Gilead Sciences to Acquire MiroBio
WEBAug 4, 2022 · MiroBio’s lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
WEBFeb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Newsroom | Gilead - Gilead Sciences
WEBGilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline. ... Find Gilead press releases and media inquiries here.
Gilead Sciences
WEBWe've revolutionized HIV treatment and prevention, delivered a cure for hepatitis C and made advancements in therapies for viral diseases and certain cancers. Now, we’ve announced our plans to enable access to our investigational medication for HIV prevention, if approved, across 120 high-incidence, resource-limited countries.
Gilead Sciences Announces Second Quarter 2022 Financial Results
WEBTotal second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C …
Gilead Sciences Announces Fourth Quarter and Full Year 2022 …
WEBFeb 2, 2023 · Fourth Quarter 2022 Financial Results. Total fourth quarter 2022 revenue of $7.4 billion increased 2% compared to the same period in 2021, primarily due to increased sales in Oncology, HIV and hepatitis C virus (“HCV”), partially offset by lower Veklury® (remdesivir) sales.
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead …
WEBJan 22, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated …
Gilead Sciences Expands Liver Portfolio With Acquisition of …
WEBFeb 12, 2024 · Seladelpar, an investigational treatment for people with PBC, is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist shown to regulate critical metabolic and liver disease pathways in indications with high unmet medical need.
Gilead Sciences Announces Third Quarter 2022 Financial Results
WEBOct 27, 2022 · Third Quarter 2022 Financial Results. Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury® (remdesivir) sales, partially offset by increased sales in …
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
WEBSep 12, 2024 · This could support the initial launch of the first and only twice-yearly HIV prevention choice in 2025. Gilead is executing an access strategy that prioritizes speed and enables the most efficient paths for the regulatory review and approval of lenacapavir for PrEP in regions around the world.